Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Kowal Investment Group LLC

Kowal Investment Group LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,384 shares of the biopharmaceutical company’s stock after purchasing an additional 176 shares during the period. Kowal Investment Group LLC’s holdings in Gilead Sciences were worth $301,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in GILD. CarsonAllaria Wealth Management Ltd. increased its position in shares of Gilead Sciences by 198.3% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 238 shares in the last quarter. Palisade Asset Management LLC acquired a new position in Gilead Sciences in the 1st quarter valued at about $29,000. Cedar Wealth Management LLC increased its position in Gilead Sciences by 51.6% in the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 160 shares during the period. Financial Connections Group Inc. acquired a new position in Gilead Sciences in the 2nd quarter valued at about $34,000. Finally, Frank Rimerman Advisors LLC acquired a new position in Gilead Sciences in the 4th quarter valued at about $36,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the sale, the insider now owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 36,847 shares of company stock valued at $3,002,940. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $83.94 on Friday. The business’s 50 day simple moving average is $76.95 and its 200-day simple moving average is $71.25. The firm has a market capitalization of $104.58 billion, a price-to-earnings ratio of 233.17, a price-to-earnings-growth ratio of 2.80 and a beta of 0.18. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.61 by $0.40. The business had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.67%. The ex-dividend date of this dividend is Friday, September 13th. Gilead Sciences’s payout ratio is currently 855.56%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on GILD shares. Royal Bank of Canada boosted their price target on Gilead Sciences from $72.00 to $74.00 and gave the company a “sector perform” rating in a research report on Wednesday, September 4th. Raymond James upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price target on the stock in a research report on Monday, July 8th. Truist Financial boosted their price target on Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Cantor Fitzgerald restated a “neutral” rating and issued a $70.00 price target on shares of Gilead Sciences in a research report on Monday, September 16th. Finally, Piper Sandler reiterated an “overweight” rating and set a $95.00 target price on shares of Gilead Sciences in a research report on Wednesday, September 11th. Twelve investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $82.06.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.